Perrigo Company (PRGO) 150.90 $PRGO
SmarTrend Watching for Potential Rebound in Shares of Perrigo After 1.65% Loss
Comtex SmarTrend(R) - Mon Feb 09, 4:31PM CST
Perrigo (NASDAQ
RGO) traded in a range yesterday that spanned from a low of $147.77 to a high of $150.49. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $148.00 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
PRGO: 150.90 (+0.22)
Perrigo Company (PRGO) CEO Joseph Papa on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Feb 07, 1:17AM CST
PRGO: 150.90 (+0.22)
Trade-Ideas: Perrigo (PRGO) Is Today's "Roof Leaker" Stock
at The Street - Fri Feb 06, 12:01PM CST
Trade-Ideas LLC identified Perrigo (PRGO) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
PRGO: 150.90 (+0.22)
Three Reasons To Let Akorn Fall Into Your Portfolio
at Investor's Business Daily - Fri Feb 06, 10:11AM CST
With a 99 IBD Composite Rating, a stock price trading at all-time highs and a recent run of robust financial growth, generic drug maker Akorn (AKRX) is already a top stock. It might show even more strength in future quarters, thanks to several trends...
PRGO: 150.90 (+0.22), ACT: 285.37 (+3.71), AKRX: 47.28 (-0.25), MYL: 55.85 (+1.34), TEVA: 56.77 (-0.58)
Perrigo Co (PRGO) Earnings Report: Q2 2015 Conference Call Transcript
at The Street - Fri Feb 06, 8:08AM CST
The following Perrigo Co (PRGO) conference call took place on February 5, 2015, 09:00 AM ET. This is a transcript of that earnings call:
PRGO: 150.90 (+0.22)
SmarTrend Watching for Potential Pullback in Shares of Perrigo After 2.34% Gain
Comtex SmarTrend(R) - Thu Feb 05, 4:13PM CST
Perrigo (NASDAQ RGO) traded in a range yesterday that spanned from a low of $150.51 to a high of $157.65. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $153.25 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PRGO: 150.90 (+0.22)
Stocks Rise In Weak Trade; LinkedIn Jumps After Hours
at Investor's Business Daily - Thu Feb 05, 4:03PM CST
All three major indexes rose 1% Thursday, led by generic-drug makers and oil stocks. But volume was light. The Dow Jones industrial average rose 1.2% while the Nasdaq and S&P 500 each climbed 1%. However, volume fell 7% on the Nasdaq and 23% on the...
SIRO: 91.06 (+0.18), GPRO: 45.27 (-0.02), PRGO: 150.90 (+0.22), BWLD: 187.27 (+0.30), PCLN: 1,103.37 (+11.42), MCO: 98.22 (+0.01), LCI: 57.78 (-0.91), LNKD: 269.00 (+1.83), CBOE: 63.01 (+0.84), EXPE: 89.49 (-0.08), TEVA: 56.77 (-0.58)
Stocks Close Near Session Highs, But Volume Softens
at Investor's Business Daily - Thu Feb 05, 3:18PM CST
Stocks closed with a flourish Thursday, although volume dwindled on both exchanges, according to preliminary data. The Nasdaq and S&P 500 rose 1% and the Dow Jones industrial average gained 1.2% in the stock market today. Generic drugmakers were the...
GPRO: 45.27 (-0.02), PRGO: 150.90 (+0.22), AKRX: 47.28 (-0.25), PFE: 34.64 (-0.23), ORLY: 205.55 (-1.02), BWLD: 187.27 (+0.30), HSP: 87.35 (unch), LCI: 57.78 (-0.91), V: 269.63 (-1.28), LNKD: 269.00 (+1.83), SNCR: 43.89 (+1.06), EXPE: 89.49 (-0.08), DD: 76.18 (-0.11), TEVA: 56.77 (-0.58), TWTR: 48.50 (+0.55)
Perrigo Beats on Earnings, FY15 Guidance In Line - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 9:15AM CST
Perrigo reported second quarter fiscal 2015 earnings of $1.82 per share.
BIIB: 391.66 (-0.45), PRGO: 150.90 (+0.22), ALNY: 95.54 (+1.67), AMAG: 41.49 (+0.23)
Perrigo ups earnings 182% in FQ2
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 9:06AM CST
PRGO: 150.90 (+0.22)
Perrigo (PRGO) Beats on Q4 Earnings, Revenues In Line - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 7:46AM CST
Perrigo (PRGO) Beats on Q4 Earnings, Revenues In Line
PRGO: 150.90 (+0.22)
Perrigo beats by $0.03, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 6:33AM CST
PRGO: 150.90 (+0.22)
Perrigo Company plc Reports Record Second Quarter Revenue, Adjusted Net Income And Adjusted Margins
PR Newswire - Thu Feb 05, 6:29AM CST
-- Fiscal second quarter net sales increased to a second quarter record of $1.07 billion.
PRGO: 150.90 (+0.22)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 4:30PM CST
FIS: 66.52 (+0.33), PRGO: 150.90 (+0.22), LAZ: 50.90 (+0.18), CHTR: 177.88 (+0.85), LQDT: 9.52 (+0.09), CFX: 52.02 (+3.84), KORS: 73.27 (+1.72), OZM: 11.93 (-0.14), PTEN: 18.14 (+1.13), DLPH: 78.70 (+0.64), DNKN: 46.70 (-0.69), DFT: 31.83 (-0.17), AMSC: 0.80 (+0.02), APO: 23.70 (+0.36), SNCR: 43.89 (+1.06), PRLB: 74.00 (+2.60), CSL: 94.14 (-0.09), SIRI: 3.83 (-0.07), PBH: 39.07 (+0.27), COTY: 22.03 (unch), RSTI: 24.12 (+0.20), IT: 81.53 (+1.64), ADS: 286.61 (+1.70), AINV: 7.71 (+0.15), AZN: 69.96 (+0.20), BCE: 44.74 (+0.14), NGD: 3.73 (-0.04), EL: 82.49 (+1.58), BCO: 25.73 (+0.18), RFP: 19.03 (+0.40), ODFL: 76.25 (+0.96), BDX: 143.71 (+0.72), GRA: 101.61 (+1.69), SNA: 145.40 (+0.71), BR: 52.59 (-0.29), BLL: 74.93 (+0.89), GRUB: 39.93 (+1.71), SBH: 33.10 (+0.28), ARW: 61.98 (+0.78), ETR: 79.12 (-1.53), BDC: 87.78 (+0.61), IVC: 17.13 (+0.15), CMI: 139.04 (+2.41), S: 5.23 (+0.08), PPL: 34.69 (-0.16), NUS: 56.92 (-1.30), MMP: 80.41 (-0.86), MMS: 59.14 (+0.12), MSCI: 57.20 (unch), MDSO: 46.58 (+1.48), ICE: 233.22 (-1.21), FBP: 6.35 (-0.02), LIOX: 5.57 (+0.10), CI: 114.47 (-0.51), PM: 82.87 (-0.82), EQT: 81.18 (+0.43), GPI: 84.34 (-0.74), ABB: 21.34 (+0.27), GPK: 15.41 (+0.29), GLT: 24.89 (+0.04), EQM: 88.04 (+0.96)
Boyden's Leadership Series Features Perrigo's Jaclyn Ahearne
Business Wire - Wed Feb 04, 4:37AM CST
Boyden, a global leader in executive search, today released a new issue of its Leadership Series, featuring an in-depth interview with Jaclyn Ahearne, Vice President of E-Commerce at Perrigo Company. Perrigo is the world's largest manufacturer of over-the-counter (OTC) pharmaceutical products for the store brand market and an industry leader in pharma technologies.
PRGO: 150.90 (+0.22)
Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 3:05PM CST
Perrigo Company (PRGO) is set to report second-quarter fiscal 2015 results on Feb 5 before the market opens.
ACT: 285.37 (+3.71), PRGO: 150.90 (+0.22), ACOR: 36.14 (-0.51), REGN: 402.40 (+0.66)
Galmed, Perrigo Tie Up for Mass Production of Aramchol API - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 4:30PM CST
Galmed Pharmaceuticals Ltd. (GLMD) signed a manufacturing services agreement with Perrigo for the large-scale production of the API in Galmed's aramchol.
PRGO: 150.90 (+0.22), GLMD: 6.80 (+0.03), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
Perrigo Company plc To Release Second Quarter Fiscal Year 2015 Results On February 5, 2015 - Updating Call Time
PR Newswire - Thu Jan 29, 7:16AM CST
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its second quarter fiscal year 2015 on Thursday, February 5, 2015 at approximately 7:30 a.m. (ET). The Company will conduct a conference call at 9:00 a.m. (ET) hosted by Joseph C. Papa, Perrigo's Chairman, President and Chief Executive Officer.
PRGO: 150.90 (+0.22)
Galmed and Perrigo Execute Manufacturing Agreement for Large-Scale Aramchol API Production
PR Newswire - Wed Jan 28, 7:00AM CST
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"
, a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol gallstones, announced today that it has entered into a Manufacturing Services Agreement with Perrigo API Ltd., a subsidiary of Perrigo Company plc (NYSE: PRGO) ("Perrigo" , for the large-scale production of the active pharmaceutical ingredient ("API" of Galmed's product candidate, aramchol. The API produced pursuant to this agreement is expected to provide sufficient quantities of aramchol for Galmed's potential future Phase III clinical trials of aramchol for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH.
PRGO: 150.90 (+0.22), GLMD: 6.80 (+0.03)
Perrigo Company to pay quarterly dividend to holders of record of 27 February 2015
M2 - Wed Jan 28, 5:33AM CST
The board of directors of Perrigo Company (NYSE RGO)(NYSE:TASE), a healthcare company, on Tuesday declared a quarterly dividend of USD0.125 per share of the company's stock.
PRGO: 150.90 (+0.22)
SmarTrend Watching for Potential Rebound in Shares of Perrigo After 1.65% Loss
Comtex SmarTrend(R) - Mon Feb 09, 4:31PM CST
Perrigo (NASDAQ
RGO) traded in a range yesterday that spanned from a low of $147.77 to a high of $150.49. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $148.00 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. PRGO: 150.90 (+0.22)
Perrigo Company (PRGO) CEO Joseph Papa on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Feb 07, 1:17AM CST
PRGO: 150.90 (+0.22)
Trade-Ideas: Perrigo (PRGO) Is Today's "Roof Leaker" Stock
at The Street - Fri Feb 06, 12:01PM CST
Trade-Ideas LLC identified Perrigo (PRGO) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
PRGO: 150.90 (+0.22)
Three Reasons To Let Akorn Fall Into Your Portfolio
at Investor's Business Daily - Fri Feb 06, 10:11AM CST
With a 99 IBD Composite Rating, a stock price trading at all-time highs and a recent run of robust financial growth, generic drug maker Akorn (AKRX) is already a top stock. It might show even more strength in future quarters, thanks to several trends...
PRGO: 150.90 (+0.22), ACT: 285.37 (+3.71), AKRX: 47.28 (-0.25), MYL: 55.85 (+1.34), TEVA: 56.77 (-0.58)
Perrigo Co (PRGO) Earnings Report: Q2 2015 Conference Call Transcript
at The Street - Fri Feb 06, 8:08AM CST
The following Perrigo Co (PRGO) conference call took place on February 5, 2015, 09:00 AM ET. This is a transcript of that earnings call:
PRGO: 150.90 (+0.22)
SmarTrend Watching for Potential Pullback in Shares of Perrigo After 2.34% Gain
Comtex SmarTrend(R) - Thu Feb 05, 4:13PM CST
Perrigo (NASDAQ
RGO) traded in a range yesterday that spanned from a low of $150.51 to a high of $157.65. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $153.25 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. PRGO: 150.90 (+0.22)
Stocks Rise In Weak Trade; LinkedIn Jumps After Hours
at Investor's Business Daily - Thu Feb 05, 4:03PM CST
All three major indexes rose 1% Thursday, led by generic-drug makers and oil stocks. But volume was light. The Dow Jones industrial average rose 1.2% while the Nasdaq and S&P 500 each climbed 1%. However, volume fell 7% on the Nasdaq and 23% on the...
SIRO: 91.06 (+0.18), GPRO: 45.27 (-0.02), PRGO: 150.90 (+0.22), BWLD: 187.27 (+0.30), PCLN: 1,103.37 (+11.42), MCO: 98.22 (+0.01), LCI: 57.78 (-0.91), LNKD: 269.00 (+1.83), CBOE: 63.01 (+0.84), EXPE: 89.49 (-0.08), TEVA: 56.77 (-0.58)
Stocks Close Near Session Highs, But Volume Softens
at Investor's Business Daily - Thu Feb 05, 3:18PM CST
Stocks closed with a flourish Thursday, although volume dwindled on both exchanges, according to preliminary data. The Nasdaq and S&P 500 rose 1% and the Dow Jones industrial average gained 1.2% in the stock market today. Generic drugmakers were the...
GPRO: 45.27 (-0.02), PRGO: 150.90 (+0.22), AKRX: 47.28 (-0.25), PFE: 34.64 (-0.23), ORLY: 205.55 (-1.02), BWLD: 187.27 (+0.30), HSP: 87.35 (unch), LCI: 57.78 (-0.91), V: 269.63 (-1.28), LNKD: 269.00 (+1.83), SNCR: 43.89 (+1.06), EXPE: 89.49 (-0.08), DD: 76.18 (-0.11), TEVA: 56.77 (-0.58), TWTR: 48.50 (+0.55)
Perrigo Beats on Earnings, FY15 Guidance In Line - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 9:15AM CST
Perrigo reported second quarter fiscal 2015 earnings of $1.82 per share.
BIIB: 391.66 (-0.45), PRGO: 150.90 (+0.22), ALNY: 95.54 (+1.67), AMAG: 41.49 (+0.23)
Perrigo ups earnings 182% in FQ2
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 9:06AM CST
PRGO: 150.90 (+0.22)
Perrigo (PRGO) Beats on Q4 Earnings, Revenues In Line - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 7:46AM CST
Perrigo (PRGO) Beats on Q4 Earnings, Revenues In Line
PRGO: 150.90 (+0.22)
Perrigo beats by $0.03, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 6:33AM CST
PRGO: 150.90 (+0.22)
Perrigo Company plc Reports Record Second Quarter Revenue, Adjusted Net Income And Adjusted Margins
PR Newswire - Thu Feb 05, 6:29AM CST
-- Fiscal second quarter net sales increased to a second quarter record of $1.07 billion.
PRGO: 150.90 (+0.22)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 4:30PM CST
FIS: 66.52 (+0.33), PRGO: 150.90 (+0.22), LAZ: 50.90 (+0.18), CHTR: 177.88 (+0.85), LQDT: 9.52 (+0.09), CFX: 52.02 (+3.84), KORS: 73.27 (+1.72), OZM: 11.93 (-0.14), PTEN: 18.14 (+1.13), DLPH: 78.70 (+0.64), DNKN: 46.70 (-0.69), DFT: 31.83 (-0.17), AMSC: 0.80 (+0.02), APO: 23.70 (+0.36), SNCR: 43.89 (+1.06), PRLB: 74.00 (+2.60), CSL: 94.14 (-0.09), SIRI: 3.83 (-0.07), PBH: 39.07 (+0.27), COTY: 22.03 (unch), RSTI: 24.12 (+0.20), IT: 81.53 (+1.64), ADS: 286.61 (+1.70), AINV: 7.71 (+0.15), AZN: 69.96 (+0.20), BCE: 44.74 (+0.14), NGD: 3.73 (-0.04), EL: 82.49 (+1.58), BCO: 25.73 (+0.18), RFP: 19.03 (+0.40), ODFL: 76.25 (+0.96), BDX: 143.71 (+0.72), GRA: 101.61 (+1.69), SNA: 145.40 (+0.71), BR: 52.59 (-0.29), BLL: 74.93 (+0.89), GRUB: 39.93 (+1.71), SBH: 33.10 (+0.28), ARW: 61.98 (+0.78), ETR: 79.12 (-1.53), BDC: 87.78 (+0.61), IVC: 17.13 (+0.15), CMI: 139.04 (+2.41), S: 5.23 (+0.08), PPL: 34.69 (-0.16), NUS: 56.92 (-1.30), MMP: 80.41 (-0.86), MMS: 59.14 (+0.12), MSCI: 57.20 (unch), MDSO: 46.58 (+1.48), ICE: 233.22 (-1.21), FBP: 6.35 (-0.02), LIOX: 5.57 (+0.10), CI: 114.47 (-0.51), PM: 82.87 (-0.82), EQT: 81.18 (+0.43), GPI: 84.34 (-0.74), ABB: 21.34 (+0.27), GPK: 15.41 (+0.29), GLT: 24.89 (+0.04), EQM: 88.04 (+0.96)
Boyden's Leadership Series Features Perrigo's Jaclyn Ahearne
Business Wire - Wed Feb 04, 4:37AM CST
Boyden, a global leader in executive search, today released a new issue of its Leadership Series, featuring an in-depth interview with Jaclyn Ahearne, Vice President of E-Commerce at Perrigo Company. Perrigo is the world's largest manufacturer of over-the-counter (OTC) pharmaceutical products for the store brand market and an industry leader in pharma technologies.
PRGO: 150.90 (+0.22)
Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 03, 3:05PM CST
Perrigo Company (PRGO) is set to report second-quarter fiscal 2015 results on Feb 5 before the market opens.
ACT: 285.37 (+3.71), PRGO: 150.90 (+0.22), ACOR: 36.14 (-0.51), REGN: 402.40 (+0.66)
Galmed, Perrigo Tie Up for Mass Production of Aramchol API - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 4:30PM CST
Galmed Pharmaceuticals Ltd. (GLMD) signed a manufacturing services agreement with Perrigo for the large-scale production of the API in Galmed's aramchol.
PRGO: 150.90 (+0.22), GLMD: 6.80 (+0.03), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
Perrigo Company plc To Release Second Quarter Fiscal Year 2015 Results On February 5, 2015 - Updating Call Time
PR Newswire - Thu Jan 29, 7:16AM CST
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its second quarter fiscal year 2015 on Thursday, February 5, 2015 at approximately 7:30 a.m. (ET). The Company will conduct a conference call at 9:00 a.m. (ET) hosted by Joseph C. Papa, Perrigo's Chairman, President and Chief Executive Officer.
PRGO: 150.90 (+0.22)
Galmed and Perrigo Execute Manufacturing Agreement for Large-Scale Aramchol API Production
PR Newswire - Wed Jan 28, 7:00AM CST
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"
, a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol gallstones, announced today that it has entered into a Manufacturing Services Agreement with Perrigo API Ltd., a subsidiary of Perrigo Company plc (NYSE: PRGO) ("Perrigo" , for the large-scale production of the active pharmaceutical ingredient ("API" of Galmed's product candidate, aramchol. The API produced pursuant to this agreement is expected to provide sufficient quantities of aramchol for Galmed's potential future Phase III clinical trials of aramchol for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH. PRGO: 150.90 (+0.22), GLMD: 6.80 (+0.03)
Perrigo Company to pay quarterly dividend to holders of record of 27 February 2015
M2 - Wed Jan 28, 5:33AM CST
The board of directors of Perrigo Company (NYSE
RGO)(NYSE:TASE), a healthcare company, on Tuesday declared a quarterly dividend of USD0.125 per share of the company's stock. PRGO: 150.90 (+0.22)
